(Q26786594)

https://api.crossref.org/works/10.1002%2FCNCR.29531

Smoking and carcinoma of the lung; preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

At least one in seven cases of cancer is caused by smoking. Global estimates for 1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Nonsmall cell lung cancer in never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Lung cancer in never smokers: change of a mindset in the molecular era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Lung cancer incidence in never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Lung cancer in never smokers--a different disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

The transcriptional landscape and mutational profile of lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Whole-genome sequencing of asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

A small-cell lung cancer genome with complex signatures of tobacco exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

KIF5B-RET fusions in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

ROS1 fusions in Chinese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Re: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

First-line crizotinib in ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Fibroblast growth factor signaling in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

FGFR1 expression and gene copy numbers in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

7 January 2021

Comprehensive Analysis of Oncogenic Mutations in Lung Squamous Cell Carcinoma With Minor Glandular Component

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

7 January 2021

Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

7 January 2021

Crizotinib in ROS1-rearranged non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29531

7 January 2021